Browse investing articles and stock analysis by Jake Lerch. Get expert financial insights and investment advice from The Motley Fool.

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

gTLD process -- The ICANN 2026 round of new generic Top-Level Domains is intended to start in Q2 2026, with no future ...

Disposition Activity -- Q3 proceeds totaled $19.3 million, with $4.6 million in gains; year-to-date sales reached $133.8 ...

Net Income -- $7.6 million, down from $9.3 million. Net income attributable to Karat ( KRT +1.51%) was $7.3 million, or $0.36 ...

Upcoming product launches -- AMP-007 inhalation on track for mid-2026 launch targeting a $1.5 billion market; generic ...

Exclusive Supply Agreement: A contractual arrangement where UFP Technologies ( UFPT 2.21%) is the sole supplier of specified ...

PN-943 (IBD Program) -- Oral, gut-restricted alpha-4-beta-7 integrin antagonist demonstrated greater than threefold improved ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.

Both of these electric air taxi pioneers have sold off hard recently, creating a potential entry point for patient investors.

A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.

One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term ...